Shares of Adaptimmune Therapeutics PLC (NASDAQ:ADAP - Get Free Report) passed above its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $0.27 and traded as high as $0.29. Adaptimmune Therapeutics shares last traded at $0.27, with a volume of 386,996 shares.
Analysts Set New Price Targets
A number of research firms have issued reports on ADAP. Barclays cut their target price on shares of Adaptimmune Therapeutics from $1.00 to $0.46 and set an "underweight" rating for the company in a research report on Wednesday, May 14th. Wells Fargo & Company cut their target price on shares of Adaptimmune Therapeutics from $1.50 to $1.00 and set an "equal weight" rating for the company in a research report on Wednesday, May 14th. Guggenheim cut their target price on shares of Adaptimmune Therapeutics from $3.00 to $1.75 and set a "buy" rating for the company in a research report on Wednesday, March 26th. Wall Street Zen initiated coverage on shares of Adaptimmune Therapeutics in a report on Friday, May 16th. They set a "buy" rating on the stock. Finally, Scotiabank cut their price target on shares of Adaptimmune Therapeutics from $3.15 to $1.40 and set a "sector outperform" rating on the stock in a report on Friday, March 21st. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $1.35.
Get Our Latest Research Report on ADAP
Adaptimmune Therapeutics Stock Up 1.1%
The firm has a market cap of $74.08 million, a P/E ratio of -1.04 and a beta of 2.18. The business's fifty day moving average price is $0.27 and its two-hundred day moving average price is $0.38. The company has a current ratio of 2.02, a quick ratio of 1.79 and a debt-to-equity ratio of 4.24.
Adaptimmune Therapeutics (NASDAQ:ADAP - Get Free Report) last released its quarterly earnings results on Tuesday, May 13th. The biotechnology company reported ($0.18) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.18). Adaptimmune Therapeutics had a negative net margin of 38.91% and a negative return on equity of 163.73%. The business had revenue of $7.29 million for the quarter, compared to the consensus estimate of $6.55 million. As a group, equities research analysts anticipate that Adaptimmune Therapeutics PLC will post -0.14 EPS for the current year.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Two Sigma Investments LP grew its stake in Adaptimmune Therapeutics by 33.5% in the 4th quarter. Two Sigma Investments LP now owns 76,347 shares of the biotechnology company's stock valued at $41,000 after buying an additional 19,146 shares during the last quarter. Virtu Financial LLC grew its stake in Adaptimmune Therapeutics by 21.5% in the 4th quarter. Virtu Financial LLC now owns 122,696 shares of the biotechnology company's stock valued at $66,000 after buying an additional 21,688 shares during the last quarter. Invesco Ltd. grew its stake in Adaptimmune Therapeutics by 82.0% in the 4th quarter. Invesco Ltd. now owns 63,335 shares of the biotechnology company's stock valued at $34,000 after buying an additional 28,526 shares during the last quarter. Rock Springs Capital Management LP grew its position in Adaptimmune Therapeutics by 2.4% in the 4th quarter. Rock Springs Capital Management LP now owns 2,483,468 shares of the biotechnology company's stock worth $1,338,000 after purchasing an additional 58,000 shares during the last quarter. Finally, Two Sigma Advisers LP grew its position in Adaptimmune Therapeutics by 492.0% in the 4th quarter. Two Sigma Advisers LP now owns 70,735 shares of the biotechnology company's stock worth $38,000 after purchasing an additional 58,787 shares during the last quarter. 31.37% of the stock is currently owned by institutional investors and hedge funds.
About Adaptimmune Therapeutics
(
Get Free Report)
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.
See Also
Before you consider Adaptimmune Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Adaptimmune Therapeutics wasn't on the list.
While Adaptimmune Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
